March 16 (Reuters) - Moderna Inc:
* MODERNA ANNOUNCES FIRST PARTICIPANT DOSED IN NIH-LED PHASE 1 STUDY OF MRNA VACCINE (MRNA-1273) AGAINST NOVEL CORONAVIRUS
* MODERNA - PREPARING FOR POTENTIAL PHASE 2 STUDY UNDER ITS OWN IND TO BUILD ON DATA FROM ONGOING PHASE 1 STUDY OF VACCINE AGAINST NOVEL CORONAVIRUS
* MODERNA INC - MANUFACTURE OF MRNA-1273 MATERIAL FOR POTENTIAL PHASE 2 TRIAL, WHICH COULD BEGIN IN A FEW MONTHS, IS UNDERWAY Source text for Eikon: Further company coverage:
